(NaturalNews) Viruses continue to mutate at increasing speeds as modern medicine fails to keep up with pathogens evolving stealthily in nature. It's even possible that modern medicine is to blame for the acceleration of virus mutation. Antiviral drugs typically attack one form of a virus. The virus quickly learns how to survive the synthetic antiviral mode of attack, evolving into stronger viruses in the evolutionary process. This creates a demand for newer drugs to stay ahead of the
mutations.

It's quite possible that Ebola's uncontrollable mutation and airborne potential is yet another side effect of a medical system that doesn't deal with the root of the problem. Still, drug companies continue to chase what they will never be able to contain, using medical methods that may save lives up front but perpetuate more harm to humankind down the road.

New Ebola vaccine to be unleashed in 2015

Johnson & Johnson is betting that the Ebola epidemic will last at least another year. Their pharmaceutical interests compel the company to invest in an Ebola vaccine. Johnson & Johnson's chief scientific officer, Paul Stoffels said the Ebola crisis is set to go on for a "a long time." He is preparing the company to develop a vaccine so the disease can be mitigated within the next year.

"At this moment we cannot predict by when the epidemic will be over [but] it's unlikely that that will happen within next 12 months in view of [its] size," said Stoffels.

At this time, the World Health Organization is prompting vaccine developers to accelerate their research programs, asking drug makers to make "as much [vaccine] as you can." Johnson & Johnson is the newest pharmaceutical giant to join the fray. Their scientific community is already looking for healthy volunteers from Africa, Europe and America who will succumb to experimental vaccine trials in early 2015. The pharmaceutical company has put forth $200 million to accelerate research. They have also invested another $43 million in a smaller vaccine developer, Vavarian Nordic. Johnson & Johnson already has plans to manufacture their own experimental vaccine, starting at 1 million doses in 2015. At least a quarter-million doses will quickly be released by May 2015 and will be directed for "broad application."

Dr. Stoffels even mentioned that Johnson & Johnson may partner with fellow pharmaceutical giant GlaxoSmithKline to speed up their ongoing research to help deliver vaccines. GSK has been working on a vaccine; their experimental trials are already being carried out in the US, UK and Mali.

The most effective of the vaccines will likely be manufactured by both pharmaceutical giants. Onlookers are still unsure what the actual effect these experimental vaccines might have on healthy people or those with allergies.

"The pharmaceuticals industry is pulling together as companies provide capability and capacity if need be," said Stoffels.

"Many companies have already reached out now to confirm they will give whatever help [is needed]," he said.

Vaccine illusions

Of course, by the time the vaccine gets around, Ebola may very well be waning, infection rates dropping, yet the vaccine will get the credit for halting Ebola in its tracks. This can be observed throughout history -- vaccines getting credit for the stoppage of disease that had already run its course. Introducing the vaccine to market at the right time is crucial for vaccine developers to continue selling it for years and decades to come. The best time to introduce the matching vaccine for the corresponding virus is when the pandemic has already reached its peak and is waning out in the population. By introducing the vaccine at the right time, an illusion is created as the scientific community praises the vaccine for saving lives. People buy it well into the future out of fear.

Learn all these details and more at the FREE online Pandemic Preparedness course at www.BioDefense.com

Sources:

http://www.telegraph.co.uk

http://science.naturalnews.com